Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 24, 2021

Veradigm and PRA Health create EHR-based clinical research network

The partnership could boost process efficiencies, accessibility and diversity of clinical trials.

Veradigm and PRA Health Sciences have partnered to establish an electronic healthcare record (EHR)-based clinical research network in the US.

The new network will reach around 25,000 physicians and 40 million patients across the country.

It leverages Veradigm’s StudySource platform, which boosts current EHR systems to comprise clinical research, along with PRA’s eSource technology and clinical research capabilities.

Physicians can use the network to provide clinical research as a care option (CRACCO) to their patients. This approach could improve clinical trials’ process efficacies, accessibility and diversity.

Veradigm Life Sciences Research business vice-president and general manager Stephanie Reisinger said: “Under this agreement, the Veradigm and PRA-led network aims to transform the clinical research processes by extending EHR workflows to include clinical research as well as fully leveraging the rich data from digital healthcare delivery.

“The scale of Veradigm’s EHR footprint with PRA’s eSource technology and deep trial expertise will enable us to literally bring studies to where the patients are.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Data management and tracking are considered long and expensive steps of a trial but most of this information is already available in EHR systems, Veradigm noted.

PRA Health’s eSource technology can automatically transfer data from Veradigm’s EHRs to an electronic data capture system, in turn expediting drug development via reduced time and effort in this step.

The automated process could also decrease transcription errors and enhance data quality while mitigating the expensive verification of source data.

PRA Health Sciences executive vice-president and chief scientific officer Kent Thoelke said: “We are evolving and modernising the drug development paradigm by integrating it with everyday healthcare delivery.”

In February this year, Irish company ICON entered an agreement to acquire PRA Health Sciences in a cash and stock deal valued at about $12bn.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU